Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact Laura on +441494 818 026 or laura@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Laura Marsh
Account Manager
laura@zenopa.com
+441494 818 026

Testimonials
I'd like to say a huge thank you to all the staff at Zenopa from initial contact to job offer. In particular I'd like to thank you to my contact for their professionalism.
Steven, 2011

Bristol-Myers Squibb to present liver disease data at EASL

5 April 2012 00:00 in Pharmaceutical Company Product News


Bristol-Myers Squibb is to showcase new clinical data on its liver disease portfolio at the forthcoming annual meeting of the European Association for the Study of the Liver (EASL).

A total of 20 abstracts from the company's portfolio will be presented at the Barcelona event this month, including data on therapies such as daclatasvir, asunaprevir, Lambda, BMS-791325, brivanib and Baraclude.

Key presentations will include analysis of clinical trial data showing the benefits its direct-acting antivirals and Lambda can offer in the treatment of hepatitis C.

The information highlighted at EASL will help expand understanding of Bristol-Myers Squibb's new therapies and support their continuing clinical development.

Dr Brian Daniels, senior vice-president for global development and medical affairs at Bristol-Myers Squibb's research and development division, said: "Bristol-Myers Squibb is at the forefront of discovering, developing and delivering potential treatments for diseases of the liver where there remains considerable unmet medical need."

Last month, the company announced a new alliance with the Duke Translational Medicine Institute, focusing on the development of new therapies in areas such as idiopathic pulmonary fibrosis.ADNFCR-8000103-ID-801334660-ADNFCR

Other news stories from 05/04/2012

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency



                    
© Copyright 2014 Zenopa Ltd